BACKGROUND: Progranulin is implicated in frontotemporal dementia (FTD), but its role in other neurodegenerative disorders is unknown. OBJECTIVE: To investigate the levels of progranulin (PGRN) in cerebrospinal fluid (CSF) in different neurodegenerative dementias and their correlation with levels in plasma in cognitively normal subjects. METHODS: We measured PGRN in CSF in 229 patients with amnestic mild cognitive impairment, Alzheimer's disease dementia, sporadic FTD, dementia with Lewy bodies, corticobasal syndrome, or progressive supranuclear palsy. We also measured PGRN in CSF and plasma in 74 cognitively normal individuals. We examined the correlation between PGRN levels in CSF and diagnosis, cortical thickness, genetic factors and other CSF biomarkers. We also investigated the correlation between plasma and CSF levels of PGRN in cognitively normal individuals. RESULTS: CSF levels did not differ across diagnoses or correlate with cortical thickness. Polymorphism rs5848 in GRN influenced CSF PGRN levels, but APOEɛ4 allele did not. Amyloid-β42, t-tau, p-tau, and YKL-40 levels correlated weakly with PGRN in CSF. We found a weak correlation (r = 0.362) between plasma and CSF PGRN levels in cognitively normal individuals. CONCLUSIONS: Our findings do not support a diagnostic value of CSF PGRN in neurodegenerative diseases. Our data confirm that levels of PGRN in plasma do not reflect accurately levels in CSF in cognitively normal controls. These data should be considered in clinical trials aiming to increase PGRN.
BACKGROUND:Progranulin is implicated in frontotemporal dementia (FTD), but its role in other neurodegenerative disorders is unknown. OBJECTIVE: To investigate the levels of progranulin (PGRN) in cerebrospinal fluid (CSF) in different neurodegenerative dementias and their correlation with levels in plasma in cognitively normal subjects. METHODS: We measured PGRN in CSF in 229 patients with amnestic mild cognitive impairment, Alzheimer's disease dementia, sporadic FTD, dementia with Lewy bodies, corticobasal syndrome, or progressive supranuclear palsy. We also measured PGRN in CSF and plasma in 74 cognitively normal individuals. We examined the correlation between PGRN levels in CSF and diagnosis, cortical thickness, genetic factors and other CSF biomarkers. We also investigated the correlation between plasma and CSF levels of PGRN in cognitively normal individuals. RESULTS: CSF levels did not differ across diagnoses or correlate with cortical thickness. Polymorphism rs5848 in GRN influenced CSF PGRN levels, but APOEɛ4 allele did not. Amyloid-β42, t-tau, p-tau, and YKL-40 levels correlated weakly with PGRN in CSF. We found a weak correlation (r = 0.362) between plasma and CSF PGRN levels in cognitively normal individuals. CONCLUSIONS: Our findings do not support a diagnostic value of CSF PGRN in neurodegenerative diseases. Our data confirm that levels of PGRN in plasma do not reflect accurately levels in CSF in cognitively normal controls. These data should be considered in clinical trials aiming to increase PGRN.
Authors: David W Fardo; Yuriko Katsumata; John S K Kauwe; Yuetiva Deming; Oscar Harari; Carlos Cruchaga; Peter T Nelson Journal: Exp Gerontol Date: 2017-02-09 Impact factor: 4.032
Authors: Camilla Lauridsen; Sigrid B Sando; Ina Møller; Guro Berge; Precious K Pomary; Gøril R Grøntvedt; Øyvind Salvesen; Geir Bråthen; Linda R White Journal: Front Aging Neurosci Date: 2017-06-28 Impact factor: 5.750
Authors: Claudia Duran-Aniotz; Paulina Orellana; Tomas Leon Rodriguez; Fernando Henriquez; Victoria Cabello; María F Aguirre-Pinto; Tamara Escobedo; Leonel T Takada; Stefanie D Pina-Escudero; Oscar Lopez; Jennifer S Yokoyama; Agustin Ibanez; Mario A Parra; Andrea Slachevsky Journal: Front Neurol Date: 2021-06-24 Impact factor: 4.003
Authors: Christopher J Holler; Georgia Taylor; Zachary T McEachin; Qiudong Deng; William J Watkins; Kathryn Hudson; Charles A Easley; William T Hu; Chadwick M Hales; Wilfried Rossoll; Gary J Bassell; Thomas Kukar Journal: Mol Neurodegener Date: 2016-06-24 Impact factor: 14.195